3-[3-phenyl-8-(trifluoromethyl)quinolin-4-yl]phenol | 854769-64-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 3-[3-phenyl-8-(trifluoromethyl)quinolin-4-yl]phenol
• 英文别名: 3-[3-Phenyl-8-(trifluoromethyl)quinolin-4-yl]phenol；3-(3-Phenyl-8-trifluoromethyl-quinolin-4-yl)-phenol
• CAS: 854769-64-5
• 化学式: C₂₂H₁₄F₃NO
• 分子量: 365.354
• InChiKey: IQLAREKDDNHGIO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6
• 重原子数：
  27
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  33.1
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3-[3-phenyl-8-(trifluoromethyl)quinolin-4-yl]phenol 、 3-羟甲基苯硼酸 在 copper diacetate 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 24.0h， 以67%的产率得到(3-{3-[3-phenyl-8-(trifluoromethyl)quinolin-4-yl]phenoxy}phenyl)methanol
  参考文献：
  名称：

  4-(3-Aryloxyaryl)quinoline alcohols are liver X receptor agonists

  摘要：

  A series of 4-(3-aryloxyaryl)quinolines with alcohol substituents on the terminal aryl ring was prepared as potential LXR agonists, in which an alcohol group replaced an amide in previously reported amide analogs. High affinity LXR ligands with excellent agonist potency and efficacy in a functional model of LXR activity were identified, demonstrating that alcohols can substitute for amides while retaining LXR activity. The most potent compound was 5b which had an IC50 = 3.3 nM for LXR beta binding and EC50 = 12 nM (122% efficacy relative to T0901317) in an ABCA1 mRNA induction assay in J774 mouse cells. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2009.10.001
• 作为产物：
  描述：

  [2-amino-3-(trifluoro-methyl)phenyl](3-hydroxyphenyl)methanone 、 苯乙醛 在 苯磺酸 作用下， 以 甲苯 为溶剂， 以79%的产率得到3-[3-phenyl-8-(trifluoromethyl)quinolin-4-yl]phenol
  参考文献：
  名称：

  4-(3-Aryloxyaryl)quinoline alcohols are liver X receptor agonists

  摘要：

  A series of 4-(3-aryloxyaryl)quinolines with alcohol substituents on the terminal aryl ring was prepared as potential LXR agonists, in which an alcohol group replaced an amide in previously reported amide analogs. High affinity LXR ligands with excellent agonist potency and efficacy in a functional model of LXR activity were identified, demonstrating that alcohols can substitute for amides while retaining LXR activity. The most potent compound was 5b which had an IC50 = 3.3 nM for LXR beta binding and EC50 = 12 nM (122% efficacy relative to T0901317) in an ABCA1 mRNA induction assay in J774 mouse cells. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2009.10.001

文献信息

• Quinolines useful in treating cardiovascular disease
  申请人：Collini D. Michael

  公开号：US20050131014A1

  公开（公告）日：2005-06-16

  This invention provides compounds of formula I that are useful in the treatment or inhibition of LXR mediated diseases.

  本发明提供了式I化合物的用途，它们在治疗或抑制LXR介导的疾病中是有用的。
• Quinoline Acids
  申请人：Wrobel Jay E.

  公开号：US20090069373A1

  公开（公告）日：2009-03-12

  This invention relates generally to quinoline-based modulators of Liver X receptors (LXRs) and related methods.

  这项发明通常涉及喹啉基调节肝X受体（LXRs）的调节剂和相关方法。
• NOVEL QUINOLINE ESTERS USEFUL FOR TREATING SKIN DISORDERS
  申请人：Bernotas Ronald Charles

  公开号：US20120010205A1

  公开（公告）日：2012-01-12

  Disclosed are quinoline esters of Formula (I): which are useful as Liver X receptors (LXR) modulators. Pharmaceutical compositions containing quinoline esters of Formula (I) and the use of quinoline esters of Formula (I) in the safe treatment of various skin disorders are also disclosed. Methods for preparing and using quinoline esters are further described.

  公开了式(I)的喹啉酯化合物，这些化合物可用作肝X受体（LXR）调节剂。还公开了含有式(I)的喹啉酯化合物的药物组合物，以及在安全治疗各种皮肤疾病中使用式(I)的喹啉酯化合物。进一步描述了制备和使用喹啉酯的方法。
• Quinolines and pharmaceutical compositions thereof
  申请人：Wyeth

  公开号：US07576215B2

  公开（公告）日：2009-08-18

  This invention provides compounds of formula I that are useful in the treatment or inhibition of LXR mediated diseases.

  本发明提供了I式化合物，可用于治疗或抑制LXR介导的疾病。
• QUINOLINES USEFUL IN TREATING CARDIOVASCULAR DISEASE
  申请人：Wyeth, A Corporation of the State of Delaware

  公开号：EP1692111A2

  公开（公告）日：2006-08-23